Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 932632, 6 pages
http://dx.doi.org/10.1155/2008/932632
Review Article

PPAR 𝛾 , PTEN, and the Fight against Cancer

1Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Received 29 February 2008; Revised 9 July 2008; Accepted 7 October 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Rosemary E. Teresi and Kristin A. Waite. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Peroxisome proliferator-activated receptor gamma (PPAR 𝛾 ) is a ligand-activated transcription factor, which belongs to the family of nuclear hormone receptors. Recent in vitro studies have shown that PPAR 𝛾 can regulate the transcription of phosphatase and tensin homolog on chromosome ten (PTEN), a known tumor suppressor. PTEN is a susceptibility gene for a number of disorders, including breast and thyroid cancer. Activation of PPAR 𝛾 through agonists increases functional PTEN protein levels that subsequently induces apoptosis and inhibits cellular growth, which suggests that PPAR 𝛾 may be a tumor suppressor. Indeed, several in vivo studies have demonstrated that genetic alterations of PPAR 𝛾 can promote tumor progression. These results are supported by observations of the beneficial effects of PPAR 𝛾 agonists in the in vivo cancer setting. These studies signify the importance of PPAR 𝛾 and PTEN's interaction in cancer prevention.